ACULAR (ketorolac tromethamine) by AbbVie is anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. Approved for postoperative pain, postoperative anterior chamber inflammation, allergic conjunctivitis and 1 more indications. First approved in 1992.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
Acular is a nonsteroidal anti-inflammatory drug (NSAID) administered as an ophthalmic solution that inhibits prostaglandin biosynthesis to reduce pain and inflammation. It is indicated for postoperative pain and inflammation following cataract surgery, allergic conjunctivitis, and seasonal allergic rhinitis. The drug has also been used off-label for systemic indications including low back pain, osteoarthritis, and lumbar spinal fusion.
This product is approaching loss of exclusivity with minimal Part D penetration, signaling a smaller brand team focused on legacy management rather than growth initiatives.
anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
Worked on ACULAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study of CU06-1004 in Patients With Daibetic Macular Edema
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Acular offers limited career growth opportunities given its mature LOE-approaching status with minimal Part D spending ($75K annually) and zero active clinical development. Roles are primarily focused on defensive brand management, generic transition planning, and maintaining existing market share rather than innovation or expansion.